{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-275674","form_type":"8-K","ticker":"SLNO","cik":"0001484565","company_name":"SOLENO THERAPEUTICS INC","filed_at":"2025-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.503363+00:00","generated_at":"2026-05-16T21:05:46.164530+00:00","sec_items":["1.01","2.03","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Soleno initiates $100M accelerated share repurchase; amends loan facility","bullets":["Entered $100M accelerated share repurchase with Jefferies; initial delivery of ~1,511,553 shares.","Repurchase expected to complete in Q1 2026; final shares based on VWAP less discount.","Amended Oxford loan facility to permit ASR; $50M committed Term C/D loans removed; remaining $100M uncommitted.","CEO cites Q3 2025 profitability and confidence in VYKAT XR launch as rationale for buyback."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-275674","json":"https://secwatch.observer/filing/0001193125-25-275674.json","markdown":"https://secwatch.observer/filing/0001193125-25-275674.md","text":"https://secwatch.observer/filing/0001193125-25-275674.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1484565/000119312525275674/0001193125-25-275674-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1484565/000119312525275674/d63564d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T21:05:46.164530+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"035906f977e75a0cb6f5688a84610e375b565d2f","claim":"SOLENO THERAPEUTICS INC amended credit facility of $100.0 million with Oxford Finance LLC.","evidence_excerpt":"the remaining $100.0 million of loans under the Loan Agreement is uncommitted and may be made available only upon the mutual agreement of the Company and the Lenders","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1484565/000119312525275674/0001193125-25-275674-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"credit facility"},{"label":"Principal","value":"$100.0 million"},{"label":"Counterparty","value":"Oxford Finance LLC"},{"label":"Event","value":"amendment"}],"fact_type":"debt_financing"},{"claim_id":"0a91cb7beefa95bc9bdfc2768787de082b18732a","claim":"SOLENO THERAPEUTICS INC incurred senior notes of $100.0 million with Jefferies LLC.","evidence_excerpt":"(the “ Company ”) entered into a confirmation and a supplemental confirmation (together, the “ ASR Agreement ”) of an accelerated share repurchase transaction with Jefferies LLC (the “ Dealer ”). Under the ASR Agreement, the Company shall repurchase an aggregate of $100.0 million of the Company’s common stock, $0.001 par value per share (the “ Common Stock ”).","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1484565/000119312525275674/0001193125-25-275674-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"senior notes"},{"label":"Principal","value":"$100.0 million"},{"label":"Counterparty","value":"Jefferies LLC"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}